Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
jak inhibitor safety in atopic dermatitis and alopecia areata a 4 5 year real world retrospective cohort study
Original title: “JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study.”
PRAC agrees new safety information on desogestrel- and etonogestrel-containing contraceptives and Litfulo, a medicine to treat alopecia areata Desogestrel- and etonogestrel-…, Agenda Agenda of the PRAC meeting 6-9 July 2026Draft Reference Number: EMA/PRAC/141965/2026…, PRAC statistics: July 2026 , PRAC statistics: July 2026 English (EN) (174.12 KB - PDF)First published: 10/07/2026 View
Original title: “Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 6-9 July 2026”
Regulator authorises deuruxolitinib for adults with extensive hair loss
Original title: “MHRA approves new treatment for severe alopecia areata”